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Objective: Ulcerative colitis (UC) is a chronic recurrent disease characterised 
by acute inflammation of the colonic mucosa. In Japan, a dietary 
supplementation product enriched with glutamine, dietary fiber, and 
oligosaccharide (GFO) is widely applied for total parenteral nutrition support. All 
three of these components have been suggested to improve intestinal health. In 
this study, we investigated to find if GFO has suppressive effects on mucosal 
damage in UC in a mouse experimental model. 
Methods: C57BL/6 mice received 2.5% of dextran sulfate sodium (DSS) in 
drinking water for 5 days to induce colitis. They then were given 0.25 mL of 
GFO or 20% of glucose solution twice daily for 10 days. Another set of mice 
receiving unaltered drinking water was used as normal control. 
Results: Body weight loss and disease activity index were significantly lower in 
GFO-treated mice compared to those in glucose-treated mice (p < 0.05). 
DSS-induced reduction of colon length was significantly alleviated in 
GFO-treated mice compared to that in glucose-treated mice (p < 0.01). In 
addition, histological findings revealed that intestinal inflammation was 
significantly attenuated in mice treated with GFO. Furthermore, treatment with 
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GFO significantly inhibited DSS-induced increase in mRNA expression of 
interleukin-1 beta. 
Conclusion: These results suggest that GFO has potential therapeutic value as 
an adjunct therapy for UC. 
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Introduction 
Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) 
characterised by acute inflammation of colonic mucosa leading to rectal 
bleeding and diarrhea. Patients with UC repeat chronic relapsing-remitting 
inflammatory conditions, and the chronic inflammation of colon is reported to 
promote the risk of colonic cancer [1]. Aminosalicylates and corticosteroids are 
applied as standard medications to reduce such intestinal mucosal 
inflammation [2]. However, in some cases, these medications have a variety of 
side effects and are not effective enough to achieve complete remission of UC 
[3]. More effective intervention with fewer side effects is required for better UC 
treatment. 
GFO is a commercial enteral supplement enriched with glutamine, dietary 
fibers, and oligosaccharide. The medicinal supplementation product is widely 
applied as enteral nutrition support and perioperative nutrition management. 
The dietary fibers contained in GFO are polydextrose and hydrolyzed guar gum, 
which are water-soluble. The oligosaccharide in GFO is lactosucrose, a kind of 
galacto-oligosaccharide. Both the fiber and the oligosaccharide are prebiotics 
that stimulate growth and activity of gastrointestinal microflora [4,5]. Previous 
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studies suggested that abnormal regulation of the mucosal immune response 
toward commensal bacterial flora plays an important role in the pathogenesis of 
UC [6]. Some reports find that administration of prebiotics such as inulin [7], 
resistant starch [8], lactulose [9], oligofructose [10] and goat’s milk 
oligosaccharides [11] effectively decrease severe clinical symptoms and 
prolong remission of intestinal mucosal inflammation by improving the intestinal 
microbial balance in rats with experimental colitis. In a human trial involving ten 
patients with Crohn’s disease (CD), administration of a fructo-oligosaccharide 
significantly reduced CD activity indices [12]. These data suggest that 
modification of intestinal microflora by GFO might be useful adjunctive 
treatment for UC. Glutamine, the other of the three constituents of GFO, is a 
major oxidative fuel for the intestine that supports intestinal mucosal functions 
[13]. Previous studies have shown that glutamine has anti-inflammatory effects 
on both intestinal epithelial cells of rodent IBD models [14,15,16] and cell lines 
[17] and biopsy samples [18] of human gut. The aim of the present study was to 
investigate the hypothesis that GFO has multiple therapeutic effects on UC by 
using mice with DSS-induced colitis. 
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Materials and methods 
Animals 
C57BL/6 male mice weighting 25-30 g and 11-wk-old (Shimizu Laboratory 
Supplies Co. Ltd., Japan) were used in this study. The mice were housed in a 
specific pathogen-free environment at ambient temperature of 23 ℃ with a 12-h 
light-dark cycle. They were given a standard chow and tap water ad libitum. All 
procedures were approved by the Animal Care Committee of Kyoto University 
Graduate School of Medicine. 
 
Induction of colitis and GFO treatment 
Experimental colitis was induced by oral administration of DSS (M 5000; 
Wako Pure Chemicals, Osaka, Japan) [19,20,21]. The mice received 2.5% 
(w/v) DSS in drinking water for 5 days, from day 0 to day 4, as previously 
described [19]. A pack of GFO (Otsuka Pharamaceutical Co., Ltd. Japan) was 
dissolved in 50 ml of distilled water. The calories and nutrient contents of the 
GFO and glucose solution are shown in Table 1. The mice received 0.25 mL of 
GFO or 20% glucose solution twice daily for 10 days, from day 0 to day 9. 
Another set of animals receiving unaltered drinking water were used for normal 
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control. On the morning after 10 full days, all mice were euthanized by cervical 
dislocation and colon samples from each of the animal groups were obtained 
for histological evaluation and RNA extraction. 
 
Determination of disease activity index 
Clinical activity of colitis was evaluated by stool consistency, hemoccult test 
(ColoScreen occult blood test, Helena Laboratories, Beaumont, TX, USA), and 
changes in body weight during the experimental period to determine the disease 
activity index (DAI), as described previously [20,22]. DAI scoring was as follows: 
weight loss (0, no change or positive change; 1, 1–5%; 2, 6–10%; 3, 11–20%; 4, 
over 21%), stool consistency (0, well-formed pellets; 2, loose stools; 4, diarrhea), 
fecal blood (0, negative hemoccult test; 2, positive hemoccult test; 4, gross 
bleeding). DAI ranging from 0 to 4 was the sum of scores for these parameters 
divided by three. 
 
Tissue sample preparation 
After measuring the length of the large intestine as an indirect marker of 
inflammation, it was washed in physiologic saline. Segments were taken from 
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0.5 cm of distal colon for analysis of mRNA expression levels of TNF-(tumor 
necrosis factor-alpha) and IL-1interleukin-1 beta). Colon samples were 
cooled with liquid nitrogen and stored at -80 ℃ until use. The rest of the 
central colon was fixed in Bouin's fluid for histological analysis. 
 
mRNA assessment by semiquantitative reverse transcription-polymerase chain 
reaction (PCR) 
Total RNA from distal colon and proximal colon was extracted using TRIzol 
solution (Invitrogen, Grand Island, NY, USA) according to the manufacturer’s 
instructions. First strand cDNA was synthesized by SuperScript™ II Reverse 
Transcriptase system (Invitrogen, Grand Island, NY, USA) according to the 
manufacturer's instructions. SYBER Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) was prepared for real-time quantitative PCR 
using ABI PRISM 7000 Sequence Detection System (Applied Biosystems, 
Foster City, CA, USA). The PCR was performed for 10 min at 90 ℃, followed 
by 50 cycles at 95 ℃ for 15 sec and at 60℃ for 1 min. The signal of each 
product was standardized against the -actin signal for each sample. Primer 
pairs for TNF-, IL-1, and -actin are shown as follows. TNF-(300 bp) : 
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5’-GGC AGG TCT ACT TTG GAG TCA TTG C-3’ and 5’-CCG AAT TCA CTG 
GAG CCT CGA ATG T-3’; IL-1 (381 bp) : 5’-GCA ACT GTT CCT GAA CTC 
A-3’ and 5’-CTG CAC TAC AGG CTC CGA G-3’; -actin (517 bp) : 5’-ATA TCG 
CTG CGC TGG TCG TC-3’ and 5’-GCT CTC CCT CAC GCC ATC CT-3’. 
 
Immunohistochemistry 
After fixing, the samples of colon were embedded in paraffin, and 3 m 
sections stained with Hematoxylin and eosin (H&E) and Periodic acid-Schiff 
reaction (PAS) were prepared. PAS stains the acidic mucin of colonic goblet 
cells a turquoise blue color. In active UC, the amount of mucin is reduced, 
particularly in more severely ulcerated areas [23]. 
 
Single oral administration of GFO 
C57BL/6 mice were fasted for 16 h and orally administered 12.5 g/kg body 
weight of GFO or 1.5g/kg body weight of glucose (same carbohydrate calorie of 
GFO). Blood samples were collected at 0, 30, and 60 min after glucose loading 
or GFO ingestion and were centrifuged at 1800 g at 4ºC for 10 min. After 
collecting supernatant of the samples, plasma and serum were stocked at –80ºC. 
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The plasma glucose levels were measured by the glucose oxidase method. 
Serum insulin levels were measured by enzyme-linked immunosorbent assay. 
Total GIP and total GLP-1 levels were measured using mouse GIP ELISA kit 
(Linco Research, St Charles, MO, USA) and mouse GLP-1 ELISA kit (Meso 
Scale Discovery, Gaithersburg, MD, USA), respectively. 
 
Statistical analysis 
All data were expressed as mean ± SE. Statistical analysis was performed 
using Student’s t-test or one-way ANOVA with Fisher’s PLSD’s post-hoc test, 
where appropriate, by using the SPSS 11.0 software (SPSS, Chicago IL, USA). 
Significant difference was considered to be present at p < 0.05. 
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Results 
Symptomatic and macroscopic changes 
Changes in body weight 
Control mice did not show significant changes in body weight throughout the 
experiment. Glucose-treated mice administered DSS showed a gradual 
decrease in body weight, one of the major symptoms of colitis [22]. The 
decrease in body weight in GFO-treated mice was significantly prevented 
compared to that in glucose-treated mice (Fig. 1). 
 
Disease activity index (DAI) 
Mice exposed to DSS during 5 days developed colitis characterized by 
decreased body weight (Fig. 1), loose stools, and fecal blood. DAI scores 
throughout the experimental period are shown in Figure 2. DAI scores were 
significantly lower in GFO-treated mice compared to those in glucose- treated 
mice on day 6, day 7 and day 9. 
 
Colon length 
Shortening of colon is generally considered a hallmark of DSS-induced 
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colonic damage. Colon shortening following DSS-induced colitis was reduced in 
GFO-treated mice compared to that in glucose-treated mice (Fig. 3). 
 
Histological appearance 
Hematoxylin and eosin (H&E) stain 
Control mice showed normal colonic structure (Fig. 4A and 4D), whereas 
the colon of glucose-treated mice administered DSS showed developed colonic 
inflammation characterized by edema, massive inflammatory cell infiltration 
(mononuclear cells, neutrophils, and eosinophils), mucosal ulceration, and 
crypt destruction (Fig. 4B and 4E). In contrast, although there was mild 
thickening of the colon wall, GFO-treated mice administered DSS showed 
much less infiltration of inflammatory cells and exhibited a relatively maintained 
mucosal structure, indicating that colonic inflammation was attenuated in 
GFO-treated mice (Fig. 4C and 4F). 
 
Periodic acid-Schiff (PAS) stain 
Control mice exhibited a high intensity of PAS staining of goblet cells and 
epithelial surface mucin through the length of the colon samples (Fig. 5A and 
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5D). On the other hand, glucose-treated DSS mice showed strongly reduced 
PAS-positive cells (Fig. 5B and 5E). In contrast, the intensity of PAS staining 
was substantially similar in control and GFO-treated DSS mice, indicating that 
GFO attenuated mucosal damage and maintained the architecture of normal 
colonic mucosa (Fig. 5C and 5F). 
 
Expression of proinflammatory cytokines 
mRNA expressions of proinflammatory cytokines, IL-1 and TNF-,in 
colonic mucosa were evaluated by real-time quantitative PCR (Fig. 6). 
IL-1mRNA levels in GFO-treated mice were significantly decreased compared 
to those in glucose-treated mice (p < 0.01). mRNA expression levels of TNF- 
tended to be lower in GFO-treated mice compared to those in glucose-treated 
mice, although the difference was not significant. 
 
Effect of GFO on GIP and GLP-1 secretion 
Fasting concentrations of glucose, insulin, and GIP and GLP-1 were similar 
in glucose-administered mice and GFO-administered mice. After administration 
of glucose and GFO, the levels of glucose, insulin and GIP were significantly 
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higher in glucose-administered mice than in GFO-administered mice (Fig. 7A, 
7B and 7C). In contrast, GLP-1 levels were significantly higher in 
GFO-administered mice than in glucose-administered mice (Fig. 7D). 
 18 
Discussion 
In the present study, we show therapeutic effects of GFO, a dietary 
supplementation product enriched with glutamine, dietary fiber, and 
oligosaccharide, on intestinal damage in mice with DSS-induced colitis. DSS 
has been utilized to experimentally induce acute and chronic models of colitis. 
Following administration of DSS solution, the mice show signs of diarrhea, 
gross rectal bleeding, weight loss, and distinctive histological phenotypes 
similar to those of UC in human subjects [21]. In this study, body weight loss, 
reduction of colon length, increased disease activity index, and histological 
abnormalities in DSS-treated mice were significantly suppressed in 
GFO-treated mice compared to those in vehicle-treated mice, demonstrating 
that GFO prevents the development of experimental UC. 
GFO is composed of glutamine, dietary fiber, and oligosaccharide. Each 
component has been reported to have beneficial effects on intestinal condition 
[4,5,13,24]. It is well known that both fiber and oligosaccharide are prebiotics 
that produce short-chain fatty acid (SCFAs) such as acetate, propionate, and 
butyrate in colon by anaerobic bacterial fermentation [25]. One of the most 
abundant SCFAs, butyrate, has been considered a major fuel source for the 
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colonocytes [26] and has been shown to increase mucosal growth and 
epithelial proliferation in both small and large intestine [27,28]. Several studies 
have reported that IBD is associated with impairment of SCFA production [29], 
and that the butyrate enema is highly effective in treating active UC [30]. 
Therefore, it is possible that GFO has a therapeutic effect by reducing mucosal 
damage through an incremental increase of SCFA production. In addition, 
glutamine is a major oxidative fuel for the intestine that supports intestinal 
mucosal functions [13]. Baskerville et al. reported that animals receiving 
intravenous infusion of glutaminase developed diarrhea, mild villous atrophy, 
mucosal ulcerations, and intestinal necrosis [31]. Additionally, supplement of 
glutamine to total parenteral nutrition solution significantly maintained height of 
intestinal villi, thicknesses of mucosa, and integrity of the intestinal wall in 
endotoxemic rats [32]. 
UC is closely associated with increased activation of intestinal immune cells, 
and most of the medications are focused on reducing the inflammation [2]. 
Pro-inflammatory cytokines, such as TNF- and IL-1 were increased in the 
colonic mucosa of UC patients [33,34]. Some reports find that administration of 
prebiotics, including lactulose, oligofructose, and goat’s milk oligosaccharides, 
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produce intestinal anti-inflammatory effects in rats with experimental colitis 
[9,10,11]. Glutamine also has been shown to have anti-inflammatory effects in 
intestinal epithelial cells of rodents in vivo [14,15,16], in a human intestinal cell 
line [17], and in primary human intestinal epithelial cells [18]. In the present 
study, GFO treatment significantly inhibited the DSS-induced increase in mRNA 
expression of IL-1. Moreover, histological findings indicate that infiltration of 
lymphocytes into mucosal tissue was significantly attenuated in GFO-treated 
mice. These findings suggest that GFO attenuates mucosal damage of UC 
partly through its anti-inflammatory effects. 
When nutrients pass through the intestine, enteroendocrine cells secrete 
many kinds of gastrointestinal hormone including gastric inhibitory polypeptide 
(GIP), glucagon-like peptide-1 (GLP-1) and GLP-2 [37]. Both GLP-1 and GLP-2 
are proglucagon-derived peptides, and are simultaneously secreted in 
response to meal ingestion from intestinal L-cells, which are located mainly in 
the distal ileum and colon [37]. GLP-1 binds to its receptor on the surface of 
pancreatic β-cells to stimulate insulin secretion. On the other hand, GLP-2 has 
various biological effects on the intestine, such as stimulation of intestinal 
mucosal growth [38], intestinal nutrient transport [39], intestinal blood flow [40], 
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and inhibition of crypt cell apoptosis [41]. In addition, human GLP-2 is reported 
to reduce the severity of colonic injury in a murine model of DSS-induced colitis 
[42]. In vivo animal studies show that some kinds of dietary fiber and SCFAs are 
potent stimulators of GLP-2 secretion [28,43]. It is also accepted that glutamine 
promotes GLP-1 secretion [35,36]. In this context, we evaluated the effect of 
single oral administration of GFO on plasma GLP-1 levels and plasma GIP 
levels in mice. GIP levels were significantly higher in glucose-administered mice 
than in GFO-administered mice probably because absorption of 
oligosaccharide contained in GFO is slower than that of glucose. In contrast, 
GLP-1 levels were extremely higher in GFO-administered mice as compared to 
those in glucose-administered mice at 30 min and 60 min after the 
administration, indicating that glutamine contained in GFO stimulates GLP-1 
secretion. Therefore, we may speculate that GFO stimulates GLP-2 secretion 
concomitantly with GLP-1 secretion, and attenuates the development of 
mucosal damage of UC via enhancement of GLP-2 secretion, although direct 
measurement of plasma GLP-2 levels is required in future. 
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Conclusion 
We demonstrate that GFO supplement (combination of glutamine, dietary 
fiber, and oligosaccharide) has therapeutic effects on DSS-induced 
experimental colitis in mice. Although further studies are needed to clarify the 
mechanism of GFO action, GFO may be a useful adjunct therapy for UC. 
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Figure legends 
Figure 1 | The effects of GFO on body weight change in mice with DSS-induced 
colitis. 
Serial changes in body weight throughout the experiment in normal control mice 
(n = 4; closed diamonds), glucose-treated mice with DSS-induced colitis (n = 5; 
closed triangles) and GFO-treated mice with DSS-induced colitis (n = 6; open 
triangles). Each value represents the mean ± SE. **p < 0.01 between control 
mice and glucose-treated mice with DSS-induced colitis. †p < 0.05 and ‡p < 0.01 
between control mice and GFO-treated mice with DSS-induced colitis.  #p < 
0.05 and ##p < 0.01 between glucose-treated and GFO-treated mice with 
DSS-induced colitis. 
 
Figure 2 | Disease activity index (DAI) of normal control mice and DSS mice 
treated with or without GFO. 
DAI combining the scores of bleeding, weight loss and stool consistency is 
divided by 3. Normal control mice (n = 4; closed diamonds), glucose-treated 
mice with DSS-induced colitis (n = 5; closed triangles) and GFO-treated mice 
with DSS-induced colitis (n = 6; open triangles). Each value represents the mean 
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± SE. *p < 0.05 and **p < 0.01 between control mice and glucose-treated mice 
with DSS-induced colitis. ‡p < 0.01 between control mice and GFO-treated mice 
with DSS-induced colitis. #p < 0.05 between glucose-treated and GFO-treated 
mice with DSS-induced colitis. 
 
Figure 3 | Colon length of normal control mice and DSS mice treated with or 
without GFO. 
Normal control mice (n = 4), glucose-treated mice with DSS-induced colitis (n = 
5) and GFO-treated mice with DSS-induced colitis (n = 6). Each value 
represents the mean ±  SE. **p < 0.01 between control mice and 
glucose-treated mice with DSS-induced colitis. ##p < 0.01 between 
glucose-treated and GFO-treated mice with DSS-induced colitis. 
 
Figure 4 | Histological findings of colon stained with Hematoxylin and eosin 
(H&E). 
Normal control mice (A and D), glucose-treated mice with DSS-induced colitis (B 
and E), and GFO-treated mice with DSS-induced colitis (C and F). Original 
magnification ; ×8 ( A, B, and C) and ×48 (D, E, and F). 
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Figure 5 | Histological findings of colon stained with Periodic acid-Schiff (PAS). 
Normal control mice (A and D), glucose-treated mice with DSS-induced colitis (B 
and E), and GFO-treated mice with DSS-induced colitis (C and F). Original 
magnification; ×8 ( A, B, and C) and ×48 (D, E, and F). 
 
Figure 6 | Real-time quantitative PCR analysis of IL-1 and TNF-mRNA 
expressions in the colon. 
(A) IL-1 mRNA expression in distal colon. (B) TNF-mRNA expression in distal 
colon. Each value represents the mean ± SE (n = 3-6). ##p < 0.01 between 
glucose-treated and GFO-treated mice with DSS-induced colitis. 
 
Figure 7 | The effects of GFO on GIP and GLP-1 secretion 
The levels of plasma glucose (A), Serum insulin (B), plasma total GIP (C) and 
plasma total GLP-1 (D) after oral ingestion of glucose (n = 7; closed circle) and 
GFO (n = 7; open circle). Each value represents the mean ± SE. *p < 0.05 and 
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